Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer

References

• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290:6–23. doi:10.1111/imr.12766.
   PubMed Web of Science ®Google Scholar
• Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr., Gutzmer R, Linette G, Chmielowski B, Lao CD, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018;36(4):383–390. doi:10.1200/JCO.2016.71.8023.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, et al. FDA Approval Summary: atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist. 2017;22:743–749. doi:10.1634/theoncologist.2017-0087.
   PubMed Web of Science ®Google Scholar
• Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA Approval Summary: pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist. 2016;21:643–650. doi:10.1634/theoncologist.2015-0498.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Domingo-Domenech E, Rueda A, Trneny M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019;37(23):1997–2007. doi:10.1200/JCO.19.00315.
   PubMed Web of Science ®Google Scholar
• Singh P, Visger Von J, Prosek J, Rovin B, Pesavento TE, Olencki T, Pandey D. Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy. Transplantation. 2019;103(2):e52–e3. doi:10.1097/TP.0000000000002502.
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–235. doi:10.1093/annonc/mdy551.
   PubMed Web of Science ®Google Scholar
• Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24:1877–1886. doi:10.1038/s41591-018-0217-1.
   PubMed Web of Science ®Google Scholar
• Wang Y, Song X, Zheng Y, Liu Z, Li Y, Qian X, Pang X, Zhang Y, Yin Y. Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment. Int J Med Sci. 2018;15:1702–1712. doi:10.7150/ijms.27643.
   PubMed Web of Science ®Google Scholar
• Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11(501):eaav7816. doi:10.1126/scitranslmed.aav7816.
   PubMed Web of Science ®Google Scholar
• Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: the STAT1: STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008;19:351–359. doi:10.1016/j.semcdb.2008.06.004.
   PubMed Web of Science ®Google Scholar
• Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN, Dome JS, Perantoni AO. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms’ tumor pathogenesis. Oncogene. 2006;25:7555–7564. doi:10.1038/sj.onc.1209742.
   PubMed Web of Science ®Google Scholar
• Goodman ML, Trinca GM, Walter KR, Papachristou EK, D’Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, et al. Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. J Immunol. 2019;202:3076–3086. doi:10.4049/jimmunol.1801152.
   PubMed Web of Science ®Google Scholar
• Glasgow MA, Argenta P, Abrahante JE, Shetty M, Talukdar S, Croonquist PA, Khalifa MA, Starr TK. Biological Insights into Chemotherapy Resistance in Ovarian Cancer. Int J Mol Sci. 2019;20(9):2131. doi:10.3390/ijms20092131.
   PubMed Web of Science ®Google Scholar
• Savant SS, Sriramkumar S, O’Hagan HM. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. Cancers. 2018;10(8):251. doi:10.3390/cancers10080251.
   Web of Science ®Google Scholar
• Levy A, Alhazzani K, Dondapati P, Alaseem A, Cheema K, Thallapureddy K, Kaur P, Alobid S, Rathinavelu A. Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors. Curr Cancer Drug Targets. 2019;19:179–188. doi:10.2174/1568009618666180706165222.
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhang L, Luo C, Jiang M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 2019;454:191–203. doi:10.1016/j.canlet.2019.04.017.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in Ovarian Cancer: are We There Yet? J Clin Oncol. 2019;37:2460–2471. doi:10.1200/JCO.19.00508.
   PubMedGoogle Scholar
• Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:viii1–viii7. doi:10.1093/annonc/mdx444.
   PubMed Web of Science ®Google Scholar
• Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, George AJT, Ghaem-Maghami S. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014;63(3):215–224. doi:10.1007/s00262-013-1503-x.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875–7880. doi:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Hu X, Ivashkiv LB. Cross-regulation of Signaling Pathways by Interferon-γ: implications for Immune Responses and Autoimmune Diseases. Immunity. 2009;31(4):539–550. doi:10.1016/j.immuni.2009.09.002.
   PubMed Web of Science ®Google Scholar
• Xu YP, Lv L, Liu Y, Smith MD, Li WC, Tan XM, Cheng M, Li Z, Bovino M, Aubé J, et al. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest. 2019;130:4316–4331. doi:10.1172/JCI129317.
   Google Scholar
• Copeland NG, Gilbert DJ, Schindler C, Zhong Z, Wen Z, Darnell JE Jr., Mui ALF, Miyajima A, Quelle FW, Ihle JN, et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics. 1995;29(1):225–228. doi:10.1006/geno.1995.1235.
   PubMed Web of Science ®Google Scholar
• Adamkova L, Souckova K, Kovarik J. Transcription protein STAT1: biology and relation to cancer. Folia Biologica. 2007;53:1–6.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19:454–465. doi:10.1016/j.cellsig.2006.09.003.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Y, Sharma N, Tarasova NI, Timofeeva OA, Winkler-Pickett RT, Tanigawa S, Perantoni AO. STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal. 2010;22:1717–1726. doi:10.1016/j.cellsig.2010.06.012.
   PubMed Web of Science ®Google Scholar
• Gordziel C, Bratsch J, Moriggl R, Knoesel T, Friedrich K. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer. 2013;109:138–146. doi:10.1038/bjc.2013.274.
   PubMed Web of Science ®Google Scholar
• Tymoszuk P, Charoentong P, Hackl H, Spilka R, Muller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat J-P, Fiegl H, et al. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer. 2014;14(1):257. doi:10.1186/1471-2407-14-257.
   PubMedGoogle Scholar
• Meissl K, Macho-Maschler S, Muller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12–20.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu ZY. STAT1 in Cancer: friend or Foe? Discov Med. 2017;24:19–29.
   PubMed Web of Science ®Google Scholar
• Chatterjee J, Dai W, Aziz NHA, Teo PY, Wahba J, Phelps DL, Maine CJ, Whilding LM, Dina R, Trevisan G, et al. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clin Cancer Res. 2017;23(13):3453–3460. doi:10.1158/1078-0432.CCR-16-2366.
   PubMed Web of Science ®Google Scholar
• Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, Joyce C, O'Brien TE, Stack MS, Stiff PJ. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J Ovarian Res. 2018;11:43. doi:10.1186/s13048-018-0414-z.
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7(2):1486–1499. doi:10.18632/oncotarget.6429.
   PubMedGoogle Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365. doi:10.1073/pnas.0611533104.
   PubMed Web of Science ®Google Scholar
• Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res. 2017;10(1):9. doi:10.1186/s13048-017-0304-9.
   PubMedGoogle Scholar
• Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28(3):651–657. doi:10.1093/annonc/mdw625.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wen H, Ju X, Bi R, Zuo W, Wu X, Shridhar V. Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One. 2017;12(1):e0170879. doi:10.1371/journal.pone.0170879.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017;28:e77. doi:10.3802/jgo.2017.28.e77.
   PubMed Web of Science ®Google Scholar
• Wang Q, Lou W, Di W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017;52:7–14. doi:10.1016/j.intimp.2017.08.017.
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141:293–302. doi:10.1016/j.ygyno.2016.03.008.
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Nelson BH. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunol Res. 2015;3:926–935. doi:10.1158/2326-6066.CIR-14-0239.
   PubMed Web of Science ®Google Scholar
• Xu M, Zhang B, Zhang M, Liu Y, Yin FL, Liu X, ZHUO S-C. Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. Oncol Lett. 2016;11:2815–2819. doi:10.3892/ol.2016.4301.
   PubMed Web of Science ®Google Scholar
• Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, et al. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol. 2019;38(2):157–170. doi:10.1097/PGP.0000000000000494.
   PubMed Web of Science ®Google Scholar
• Au KK, Le Page C, Ren R, Meunier L, Clement I, Tyrishkin K, Peterson N, Kendall-Dupont J, Childs T, Francis JA, et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J Pathol Clin Res. 2016;2:259–270. doi:10.1002/cjp2.55.
   PubMedGoogle Scholar
• Josahkian JA, Saggioro FP, Vidotto T, Ventura HT, Candido Dos Reis FJ, de Sousa CB, Tiezzi DG, de Andrade JM, Koti M, Squire JA, et al. Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome. Int J Gynecol Cancer. 2018;28(3):459–465. doi:10.1097/IGC.0000000000001193.
   PubMed Web of Science ®Google Scholar
• Koti M, Siu A, Clement I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson A-M, Squire JA. Erratum: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;113(12):1746. doi:10.1038/bjc.2015.459.
   PubMed Web of Science ®Google Scholar
• Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. J Control Release. 2019;311-312:125–137. doi:10.1016/j.jconrel.2019.08.034.
   PubMed Web of Science ®Google Scholar
• Tian X, Guan W, Zhang L, Sun W, Zhou D, Lin Q, Ren W, Nadeem L, Xu G. Physical interaction of STAT1 isoforms with TGF-beta receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer. J Exp Clin Cancer Res. 2018;37:103. doi:10.1186/s13046-018-0773-8.
   PubMed Web of Science ®Google Scholar